Current status and direct medical cost of amyotrophic lateral sclerosis in the region of Catalonia: A population-based analysis

Autoři: Josep Darbà aff001
Působiště autorů: Universitat de Barcelona, Barcelona, Spain aff001
Vyšlo v časopise: PLoS ONE 14(10)
Kategorie: Research Article



Amyotrophic lateral sclerosis is a neurodegenerative disease that leads to motor weakness. There is no cure, and treatment focuses on slowing down progression, which is achieved by a multidisciplinary approach. Hence, it is vital to understand the population needs for an optimal management of the disease.


To evaluate the current status of amyotrophic lateral sclerosis in the region of Catalonia, how the disease is managed and its direct medical costs.


Records corresponding to 841 patients diagnosed between the year 2007 and 2017 were analysed in a retrospective population-based study, including data from primary care centres, hospitals (inpatient and outpatient care), extended care facilities and mental health centres.


Mean diagnosis age was 66.11 years (SD = 12.61) and 52.79% of admitted patients were males. On average, 14.91 months elapsed between diagnosis and death, and the mean age of death was 72.64 years (SD = 12.00). Patients were admitted 10.70 times per year, mostly into primary care (86.50%), although most expenses were concentrated in hospital inpatient care. The mean cost per patient per year was €1,168. The 83.24% of patients had more than 4 systems affected by chronic conditions.


Primary care is of utmost importance in ALS attention in Catalonia, which may have a direct impact in reducing hospitalisation costs. Nonetheless, the expenses linked to inpatient care represent the biggest portion of total costs. Patients’ healthcare usage patterns and the high proportion of patients with multiple chronic conditions should be taken into account in order to adapt and improve guidelines and healthcare systems.

Klíčová slova:

Amyotrophic lateral sclerosis – Health care facilities – Health economics – Hospitals – Inpatients – Outpatients – Primary care – Spain


1. Hardiman O, Al-Chalabi A, Chio A, Corr EM, Logroscino G, Robberecht W et al. Amyotrophic lateral sclerosis. Nat Rev Dis Primers. 2017 Oct 5; 3:17071. doi: 10.1038/nrdp.2017.71 28980624

2. Mathis S, Goizet C, Soulages A, Vallat JM, Masson GL. Genetics of amyotrophic lateral sclerosis: A review. J Neurol Sci. 2019 Feb 21; 399:217–26. doi: 10.1016/j.jns.2019.02.030 30870681

3. Grad LI, Rouleau GA, Ravits J, Cashman NR. Clinical Spectrum of Amyotrophic Lateral Sclerosis (ALS). Cold Spring Harb Perspect Med. 2017 Aug 1; 7(8).

4. Logroscino G, Traynor BJ, Hardiman O, Chiò A, Mitchell D, Swingler RJ et al. Incidence of amyotrophic lateral sclerosis in Europe. J Neurol Neurosurg Psychiatry. 2010 Apr; 81(4):385–90. doi: 10.1136/jnnp.2009.183525 19710046

5. López-Bastida J, Perestelo-Pérez L, Montón-Álvarez F, Serrano-Aguilar P, Alfonso-Sanchez JL. Social economic costs and health-related quality of life in patients with amyotrophic lateral sclerosis in Spain. Amyotroph Lateral Scler. 2009 Aug; 10(4):237–43. doi: 10.1080/17482960802430781 18821088

6. Martínez-Campo Y, Homedes C, Lazaro A, Alarcón R, Campo D, Riera M, Domínguez R, Povedano M, Casasnovas C. Observational study of patients in Spain with amyotrophic lateral sclerosis: correlations between clinical status, quality of life, and dignity. BMC Palliat Care. 2017; 16: 75. doi: 10.1186/s12904-017-0260-6 29258495

7. Soriani MH, Desnuelle C. Care management in amyotrophic lateral sclerosis. Rev Neurol (Paris). 2017 May; 173(5):288–99.

8. Garrison LP Jr, Neumann PJ, Erickson P, Marshall D, Mullins CD. Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report. Value Health. 2007 Sep-Oct; 10(5):326–35. doi: 10.1111/j.1524-4733.2007.00186.x 17888097

9. Catalunya. RESOLUCIÓ SLT/353/2013, de 13 de febrer, sobre la revisió de preus públics corresponents als serveis sanitaris que presta l’Institut Català de la Salut. (DOGC núm. 6326–1.3.2013).

10. Catalunya. Ordre SLT/235/2013, de 9 de setembre, per la qual s'estableixen per a l'any 2013 els valors de les unitats de pagament per a la contraprestació dels serveis duts a terme pels centres sociosanitaris (DOGC núm. 6478–11.10.2013).

11. Monterde D, Vela E, Clèries M, grupo colaborativo GMA. Adjusted morbidity groups: A new multiple morbidity measurement of use in Primary Care. Atención Primaria. 2016; 48(10):674–82. doi: 10.1016/j.aprim.2016.06.003 27495004

12. Riancho J, Lozano-Cuesta P, Santurtún A, Sánchez-Juan P, López-Vega JM, Berciano J, et al. Amyotrophic Lateral Sclerosis in Northern Spain 40 Years Later: What Has Changed? Neurodegener Dis. 2016; 16(5–6):337–41. doi: 10.1159/000445750 27188850

13. Takei K, Tsuda K, Takahashi F, Hirai M, Palumbo J. An assessment of treatment guidelines, clinical practices, demographics, and progression of disease among patients with amyotrophic lateral sclerosis in Japan, the United States, and Europe. Amyotroph Lateral Scler Frontotemporal Degener. 2017 Oct; 18(sup1):88–97. doi: 10.1080/21678421.2017.1361445 28872912

14. Chiò A, Logroscino G, Hardiman O, Swingler R, Mitchell D, Beghi E et al. Prognostic factors in ALS: A critical review. Amyotroph Lateral Scler. 2009 Oct-Dec; 10(5–6):310–23. doi: 10.3109/17482960802566824 19922118

15. Borkan J, Eaton CB, Novillo-Ortiz D, Rivero Corte P, Jadad AR. Renewing primary care: lessons learned from the Spanish health care system. Health Aff (Millwood). 2010 Aug; 29(8):1432–41.

16. Jackson CE, McVey AL, Rudnicki S, Dimachkie MM, Barohn RJ. Symptom Management and End-of-Life Care in Amyotrophic Lateral Sclerosis. Neurol Clin. 2015 Nov; 33(4):889–908. doi: 10.1016/j.ncl.2015.07.010 26515628

17. Guidelines for the treatment of amyotrophic lateral sclerosis (ALS) in Spain. [Guía para la atención de la esclerosis lateral amiotrófica (ELA) en España]. Spanish Ministry of Health, 2009.

18. Andersen PM, Borasio GD, Dengler R, Hardiman O, Kollewe K, Leigh PN, et al. EFNS task force on management of amyotrophic lateral sclerosis: guidelines for diagnosing and clinical care of patients and relatives. Eur J Neurol. 2005 Dec; 12(12):921–38. doi: 10.1111/j.1468-1331.2005.01351.x 16324086

19. Diagnosis and treatment of amyotrophic lateral sclerosis. [Diagnòstic i tractament de l’esclerosi lateral amiotròfica]. Catalan Society of Neurology, 2011.

20. Report of the Project of Stratification of the Population in GMA groups in the National Health System (2014–2016). [Informe del proyecto de Estratificación de la Población por Grupos de Morbilidad Ajustados (GMA) en el Sistema Nacional de Salud (2014–2016)]. Spanish Ministry of Health, 2018.

21. Turner MR, Goldacre R, Ramagopalan S, Talbot K, Goldacre MJ. Autoimmune disease preceding amyotrophic lateral sclerosis: an epidemiologic study. Neurology. 2013 Oct 1; 81(14): 1222–5. doi: 10.1212/WNL.0b013e3182a6cc13 23946298

22. Gunton A, Hansen G, Schellenberg KL. Hospital utilization for patients with amyotrophic lateral sclerosis in saskatoon, Canada. Amyotroph Lateral Scler Frontotemporal Degener. 2018 May; 19(3–4):201–205. doi: 10.1080/21678421.2017.1400071 29160128

23. Goutman SA. Diagnosis and Clinical Management of Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders. Continuum (Minneap Minn). 2017 Oct; 23(5, Peripheral Nerve and Motor Neuron Disorders):1332–59.

Článek vyšel v časopise


2019 Číslo 10
Nejčtenější tento týden